Lymphadenitis Treatment Guidelines

Introduction to Lymphadenitis

• Lymph nodes affected by lymphadenitis may enlarge during treatment but typically do not remain permanently enlarged after the resolution of the underlying infection, according to the American Thoracic Society 1
• Affected lymph nodes may enlarge while patients are receiving appropriate therapy or even after the end of treatment without evidence of bacteriological relapse, as noted by the American Thoracic Society 1
• New nodes can occasionally appear during or after treatment, as reported by the American Thoracic Society 1

Diagnosis and Evaluation

• The diagnosis of suppurative lymphadenitis should be confirmed with evaluation of lymph node characteristics, including location, size, tenderness, fluctuation, presence of overlying skin changes, and single vs. multiple nodes, as recommended by the American College of Physicians 2
• Re-evaluation is recommended within 3-7 days after initiation of therapy, and if no improvement, reassess diagnosis, consider resistant organisms, evaluate for surgical drainage, and consider biopsy for histopathology and culture, as per the American College of Physicians guidelines 2
• The American Academy of Family Physicians suggests re-evaluation every 3-6 months until resolution for any lymphadenopathy without clear diagnosis, as stated in the American Family Physician in 2004 3

Treatment Regimens

• In tuberculous lymphadenitis, a 6-9 month regimen containing isoniazid (INH) and rifampin (RIF) is recommended by the Infectious Diseases Society of America 4
• For nontuberculous mycobacterial (NTM) infections, the primary treatment is excisional surgery, with a success rate of approximately 95%, and if antibiotics are needed, clarithromycin-based regimens for 6-12 months may be considered, according to the American Academy of Pediatrics 5
• First-line treatment for early, non-fluctuant suppurative lymphadenitis involves coverage for S. aureus and Streptococcus species, with options including Clindamycin 300 mg three times daily or Trimethoprim-sulfamethoxazole 160-800 mg twice daily, for a duration of 10-14 days, as recommended by the American College of Physicians 2
• The American Academy of Dermatology recommends a combination of clindamycin and rifampin for more severe cases of suppurative lymphadenitis 6
• Tetracyclines can be used for mild to moderate cases of suppurative lymphadenitis, with consideration of local resistance patterns, particularly for MRSA 6

Surgical Interventions

• Therapeutic lymph node excision is not routinely indicated except in unusual circumstances, as stated by both the American Thoracic Society and the Infectious Diseases Society of America 1, 4
• For large lymph nodes that are fluctuant and appear to be about to drain spontaneously, aspiration or incision and drainage may be beneficial, as suggested by the American Thoracic Society 1
• Complete excisional drainage is recommended rather than incision and drainage for suppurative lymphadenitis, to prevent persistent disease, sinus tract formation, and chronic drainage, and to allow for histopathological examination and culture, as per the Infectious Diseases Society of America guidelines 2
• Surgical drainage is indicated for fluctuant lymph node, failed antibiotic therapy, or systemic symptoms, and should not be delayed when indicated by fluctuance or failure to respond to antibiotics, as recommended by the American College of Surgeons 4
• Excisional biopsy is indicated for lymph nodes that persist or enlarge despite appropriate therapy, nodes with concerning features for malignancy, or diagnostic uncertainty after initial evaluation, according to Modern Pathology in 2001 7

Treatment Outcomes and Protocols

• Most uncomplicated lymphadenitis resolves completely within 1-6 months after appropriate treatment, according to the American Thoracic Society 5
• The following treatment protocols are recommended:

5, 1, 8

• For tuberculosis, a 6-9 month regimen with INH and RIF-containing regimens is recommended, with an initial 2-month phase including INH, RIF, PZA, and EMB, and a continuation phase with INH and RIF, as per the Centers for Disease Control and Prevention guidelines 4
• For Melioidosis (Burkholderia pseudomallei), treatment options include Ceftazidime, imipenem, or meropenem, as recommended by the Infectious Diseases Society of America 2
• For Chancroid (Haemophilus ducreyi), treatment options include Azithromycin 1g orally in a single dose, Ceftriaxone 250 mg IM in a single dose, Ciprofloxacin 500 mg orally twice daily for 3 days, or Erythromycin 500 mg orally four times daily for 7 days, as per the CDC recommendations 9